Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol by Hamada, Shota & Gulliford, Martin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/jgs.14215
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Hamada, S., & Gulliford, M. (2016). Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in
Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol. Journal of the American Geriatrics
Society, 64(7), 1425-31. 10.1111/jgs.14215
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
CLINICAL INVESTIGATIONS
Mortality in Individuals Aged 80 and Older with Type 2
Diabetes Mellitus in Relation to Glycosylated Hemoglobin,
Blood Pressure, and Total Cholesterol
Shota Hamada, DrPH,* and Martin C. Gulliford, MA*†
OBJECTIVES: To evaluate whether low glycosylated
hemoglobin (HbA1c), blood pressure (BP), and total
cholesterol (TC) are associated with lower risk of all-cause
mortality in very old individuals with type 2 diabetes mel-
litus.
DESIGN: Population-based cohort study.
SETTING: Primary care database in the United Kingdom.
PARTICIPANTS: Individuals aged 80 and older with type
2 diabetes mellitus (N = 25,966).
MEASUREMENTS: Associations between baseline
HbA1c, BP, and TC and all-cause mortality were evalu-
ated in Cox proportional hazards models. Analyses were
adjusted for sex, age, duration of diabetes mellitus, life-
style variables, HbA1c, BP, TC, comorbidities, prescribing
of antidiabetic and cardiovascular drugs, and participants’
general practice.
RESULTS: There were 4,490 deaths during follow-up
(median 2.0 years; mortality 104.7 per 1,000 person-
years). Mortality in participants with low (<6.0%
(<42 mmol/mol)) or high (≥8.5% (≥69 mmol/mol)) HbA1c
was similar to that in those with the reference HbA1c
(8.0–8.4% (64–68 mmol/mol)). Mortality was lowest in
individuals with HbA1c of 7.0–7.4% (53–57 mmol/mol)
(80.9 per 1,000 person-years, adjusted hazard ratio
(aHR) = 0.80, 95% confidence interval (CI) = 0.70–0.91,
P = .001). Mortality was higher in individuals with lower
BP (e.g., <130/70 mmHg, 151.7 per 1,000 person-years,
aHR = 1.52, 95% CI = 1.34–1.72, P < .001 vs reference
BP <150/90 mmHg) and in the lowest TC category
(<3.0 mmol/L, 138.7 per 1,000 person-years, aHR = 1.42,
95% CI = 1.24–1.64, P < .001 vs reference TC 4.5–
4.9 mmol/L). The relationship between TC and mortality
varied according to sex and prescription of lipid-lowering
drugs.
CONCLUSION: Low HbA1c, BP, and TC may be associ-
ated with higher mortality in very old adults with type 2
diabetes mellitus. Further research is required to under-
stand these associations and to identify optimal treatment
targets in this population. J Am Geriatr Soc 2016.
Key words: aged 80 and older; blood pressure; choles-
terol; HbA1c; type 2 diabetes mellitus
Recent increases in life expectancy have resulted inincreasing numbers of people living to very advanced
ages. Very old people (≥80) are an increasingly important
group of health services users, often having multiple
chronic conditions and requiring multiple medications.1,2
Type 2 diabetes mellitus has become a particular concern
for older people. In the United Kingdom, two-thirds of
individuals with diabetes mellitus are aged 60 and older,
and 13% are aged 80 and older.3 Despite the high preva-
lence of type 2 diabetes mellitus in very old adults, evi-
dence to inform management of individuals aged 80 and
older is limited because this older population is seldom
included in clinical trials.4,5 Treatment decisions for older
adults may be largely based on professional opinion, draw-
ing on evidence from younger adults but taking into
account a range of concerns, such as comorbidities, declin-
ing physical and cognitive functioning, and perceptions of
life expectancy, which may not be relevant in younger
people.6
Cardiovascular disease (CVD) is the leading cause of
mortality in individuals with diabetes mellitus,7,8 and clini-
cal guidelines stress the importance of cardiovascular risk
reduction by lowering blood glucose, blood pressure (BP),
and cholesterol in individuals with diabetes mellitus.6,9
There is concern that risk factor reduction may not always
be optimal. The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study found higher mortality in the
intensive glucose-lowering group.10 Additional evidence
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has emerged from observational studies that risk of mor-
tality is greater with low glycosylated hemoglobin
(HbA1c), BP, and cholesterol in individuals with type 2
diabetes mellitus,11–15 but it is uncertain whether the rela-
tionships between mortality and these cardiovascular risk
factors in younger individuals can be applied to very old
adults with diabetes mellitus because evidence is limited
and results are inconclusive.12,16–18 This study aimed to
provide new evidence by testing the hypothesis that lower
HbA1c, BP, and total cholesterol (TC) are associated with
lower risk of all-cause mortality in very old adults with
type 2 diabetes mellitus.
METHODS
Data Source
This study was conducted using the U.K. Clinical Practice
Research Datalink (CPRD), which contains anonymized
longitudinal electronic health records of 5.7 million active
individuals from 680 general practices across the United
Kingdom.19 Data on prescriptions and diagnoses in the
CPRD have been shown to be valid.20 Results of physical
examinations and biochemical tests are also recorded. The
CPRD Independent Scientific Advisory Committee
approved this study (ISAC Protocol 14_053).
Study Design and Participants
A population-based cohort study was designed including
people aged 80 and older with type 2 diabetes mellitus as
of January 1, 2012 (index date). Individuals were included
if they contributed data between January 1 and December
31, 2011 (baseline). The date of diagnosis of diabetes mel-
litus was defined as the first diagnosis of diabetes mellitus,
including HbA1c of ≥6.5% (≥48 mmol/mol), or first pre-
scription of antidiabetic drugs. Prevalent diabetes mellitus
was further confirmed during the baseline period based on
diagnosis, prescription of antidiabetic drugs, and mean
HbA1c. Individuals were excluded if they were diagnosed
with type 1 or other specific types of diabetes mellitus,
were first diagnosed with diabetes mellitus before the age
of 30, or had been prescribed insulin within 180 days of
the date of diagnosis. The details of study cohort selection
are illustrated in Figure S1.
Measurement
Records for smoking status, body mass index (BMI),
HbA1c, BP, and TC were evaluated during the 12-month
baseline period. Smoking status and BMI were carried for-
ward or carried back from data before or after baseline if
participants did not have valid data in the baseline period.
When participants had two or more valid values in the
baseline period, mean values were used for analyses. Pre-
scribed medicines were also evaluated for antidiabetic and
cardiovascular drugs, including antihypertensive, lipid-low-
ering, oral antiplatelet, and oral anticoagulant drugs.
Number of physician visits was counted in the baseline
period as a proxy for intensity of observation. Comorbidi-
ties were analyzed using clinical records for coronary heart
disease (CHD) and stroke. Age, sex, and duration of
diabetes mellitus were measured at the index date. Deaths
were ascertained from CPRD records. Records were cen-
sored when participants’ CPRD records ended.
Analysis
Baseline characteristics of the study cohort were described,
including age, sex, duration of diabetes mellitus, smoking
status, BMI, frequency of physician visits, comorbidities,
and medications. Time-to-event analyses were conducted
from the end of the baseline period to earliest of death,
date of transferred out of the practice, or December 31,
2013. Mortality (per 1,000 person-years) was calculated.
Associations between HbA1c, BP, and TC and all-
cause mortality were estimated as unadjusted and adjusted
hazard ratios (HRs) with 95% confidence intervals (CIs)
from Cox proportional hazards models. HRs were esti-
mated for HbA1c categories of <6.0%, 6.0% to 6.4%,
6.5% to 6.9%, 7.0% to 7.4%, 7.5% to 7.9%, ≥8.5%,
and missing and compared with 8.0% to 8.4% as refer-
ence (<42, 42–47, 48–52, 53–57, 58–63, ≥69 mmol/mol,
and missing vs 64–68 mmol/mol); systolic BP/diastolic BP
categories of <130/70, <135/75, <140/80, <145/85, <155/
95, ≥155/95 mmHg, and missing and compared with
<150/90 mmHg as reference; and TC categories of less
than 3.0, 3.0 to 3.4, 3.5 to 3.9, 4.0 to 4.4, 5.0 to 5.4,
≥5.5 mmol/L, and missing and compared with 4.5 to
4.9 mmol/L as reference. The reference categories were
selected according to the relaxed treatment targets for
older adults with diabetes mellitus.6 The relationships
between HbA1c, BP, and TC and mortality were visualized
using two-way quadratic prediction plots.
Four adjusted Cox models were constructed to evalu-
ate the associations between HbA1c, BP, and TC and mor-
tality adjusted for age and sex (Model 1); adjusted for age,
sex, duration of diabetes mellitus (<5, 5–9, 10–14,
≥15 years), and prescription of antidiabetic drugs (Model
2); adjusted for age, sex, duration of diabetes mellitus,
HbA1c, BP, TC (categorized as described above), and pre-
scription of antidiabetic and cardiovascular drugs (Model
3); and age, sex, duration of diabetes mellitus, HbA1c, BP,
TC, prescription of antidiabetic and cardiovascular drugs,
smoking status (never, former, current), BMI (<18.5, 18.5–
24.9, 25.0–29.9, ≥30.0 kg/m2, missing), previous diagnoses
of CVD (CHD or stroke), frequency of physician visits
(<10, 10–19, 20–29, ≥30 per year), and clustering accord-
ing to general practice (Final model). The proportional
hazards assumption was assessed using Schoenfeld residu-
als and by inspecting log-log plots, and all covariates were
retained in the models without adjustment.
Interactions between HbA1c, BP, or TC and sex; pre-
scription of antidiabetic, antihypertensive, or lipid-lower-
ing drugs, respectively; or a previous history of
cardiovascular events were tested. Stratified analyses were
conducted according to the effect modifiers identified. To
address the question of reverse causality, the analysis was
conducted after excluding participants who died in the first
6 months of follow-up. Thus, low HbA1c, BP, and TC
may result from poor health status, which might also influ-
ence the intensity of diabetes management. In addition, the
main analysis was repeated to identify high-risk categories
of HbA1c, BP, and TC for all-cause mortality, with the
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lowest-risk categories in the main analysis as reference,
and the number of different high-risk categories was evalu-
ated. All analyses were performed using Stata version 13
(Stata Corp., College Station, TX).
RESULTS
Baseline Characteristics
Baseline characteristics of participants, including comor-
bidities and medications, are shown in Table 1. The cohort
comprised 25,966 participants, with 53% women, 90%
aged 80 to 89 years, and 48% having had diabetes melli-
tus for longer than 10 years. A previous diagnosis of CHD
was recorded in 35% of participants and of stroke in
11%. Eighty-four percent of participants were prescribed
antidiabetic medications, and the most frequently pre-
scribed antidiabetic drug was metformin (n = 15,720,
61%), followed by sulphonylureas (n = 10,930, 42%)
and insulin (n = 3,436, 13%). Eighty-six percent of
participants were prescribed antihypertensive drugs, and
70% received renin-angiotensin system blockers
(n = 18,296). Lipid-lowering drugs, predominantly statins,
were also frequently prescribed (77%). Fifty-five percent of
participants received antiplatelet medications, and 12%
received anticoagulants.
Pharmacological Treatment According to Category
Pharmacological treatment is shown according to HbA1c,
BP, and TC categories in Table 2. In this cross-sectional
observation, in the baseline period, the majority of partici-
pants were treated with antidiabetic, antihypertensive, and
lipid-lowering drugs. Participants with higher HbA1c were
more frequently prescribed antidiabetic drugs, and those
with higher BP were more frequently prescribed antihyper-
tensive drugs. Most participants with low TC levels and
approximately half of those with high TC levels received
lipid-lowering drugs. Two-thirds of participants with miss-
ing HbA1c, BP, or TC values during the 12-month base-
line period were under antidiabetic, antihypertensive, or
lipid-lowering medications.
Mortality
There were 4,490 deaths (17.3%, 104.7 per 1,000 person-
years) in the follow-up period (median 2.0 years; 42,885
Table 1. Baseline Characteristics of the Study Popula-
tion (N = 25,966)
Characteristic n (%)
Age
80–84 16,643 (64)
85–89 6,803 (26)
90–94 2,103 (8)
≥95 417 (2)
Sex
Male 12,143 (47)
Female 13,823 (53)
Duration of diabetes mellitus, years
<5 4,713 (18)
5–9 8,762 (34)
10–14 6,359 (24)
≥15 6,132 (24)
Smoking statusa
Never 13,672 (53)
Former 9,796 (38)
Current 2,498 (10)
Body mass index, kg/m2a
<18.5 288 (1)
18.5–24.9 6,313 (24)
25.0–29.9 9,520 (37)
≥30.0 7,299 (28)
Missing 2,546 (10)
Number of physician visits in past 12 months
<10 3,355 (13)
10–19 9,469 (36)
20–29 6,535 (25)
≥30 6,607 (25)
Comorbidities
Coronary heart disease 9,184 (35)
Stroke 2,788 (11)
Medications (past 12 months)
Antidiabetic drugs 21,827 (84)
Antihypertensive drugs 22,456 (86)
Lipid-lowering drugs 20,102 (77)
Antiplatelets 14,297 (55)
Anticoagulants 3,170 (12)
aFigures are carried forward or carried back from data before or after
baseline.
Table 2. Pharmacological Treatment According to
Glycosylated Hemoglobin (HbA1c), Blood Pressure,
and Total Cholesterol Categories
Factor N Treated, n (%)
Antidiabetic drugs according to HbA1c category, % (mmol/mol)
<6.0 (<42) 1,387 1,387 (100)a
6.0–6.4 (42–47) 2,976 2,976 (100)a
6.5–6.9 (48–52) 7,463 5,057 (68)
7.0–7.4 (53–57) 4,700 3,915 (83)
7.5–7.9 (58–63) 2,777 2,548 (92)
8.0–8.4 (64–68) 1,780 1,698 (95)
≥8.5 (≥69) 3,006 2,950 (98)
Missing 1,877 1,296 (69)
Antihypertensive drugs according to blood pressure category, mmHg
<130/70 4,116 3,519 (89)
≥130/70 & <135/75 4,416 3,742 (85)
≥135/75 & <140/80 4,749 4,102 (86)
≥140/80 & <145/85 4,746 4,129 (87)
≥145/85 & <150/90 2,534 2,251 (89)
≥150/90 & <155/95 1,717 1,553 (90)
≥155/95 2,663 2,466 (93)
Missing 1,025 694 (68)
Lipid-lowering drugs according to total cholesterol category, mmol/L
<3.0 2,033 1,928 (95)
3.0–3.4 3,857 3,592 (93)
3.5–3.9 5,247 4,624 (88)
4.0–4.4 4,666 3,741 (80)
4.5–4.9 3,158 2,155 (68)
5.0–5.4 1,822 1,026 (56)
≥5.5 2,288 1,137 (50)
Missing 2,895 1,899 (66)
aIndividuals with mean HbA1c <6.5% (<48 mmol/mol) and no prescrip-
tion of antidiabetic drugs in the baseline period were excluded from the
study cohort.
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person-years). The distribution of deaths according to
HbA1c, BP, and TC categories and unadjusted and fully
adjusted HRs are shown in Table 3. Cox models adjusted
for a range of covariates and HRs are shown in Table S1.
A U-shaped relationship between HbA1c and mortality
was observed (Figure S2). Mortality was 111.5 per 1,000
person-years in participants with the reference HbA1c cat-
egory (8.0–8.4%, 64–68 mmol/mol). Mortality in partici-
pants with low (<6.0%, <42 mmol/mol) or high (≥8.5%,
≥69 mmol/mol) HbA1c was similar to that in those with
the reference HbA1c category. Mortality in participants
with baseline HbA1c of 7.0% to 7.4% (53–57 mmol/mol)
was lowest (80.9 per 1,000 person-years, adjusted HR
(aHR)=0.80, 95% CI=0.70–0.91, P = .001).
There appeared to be a reverse J-shaped relationship
between BP and mortality (Figure S2). Mortality was 80.5
per 1,000 person-year in participants with the reference BP
category (<150/90 mmHg). Mortality was 151.7 per 1,000
person-years in participants in the lowest BP category
(<130/70 mmHg) (aHR = 1.52, 95% CI = 1.34–1.72,
P < .001) and 112.3 per 1,000 person-years in participants
in the second lowest BP category (<135/75 mmHg)
(aHR=1.30, 95% CI=1.14–1.48, P < .001). Missing BP
was also associated with higher mortality (aHR = 1.38,
95% CI=1.18–1.61, P < .001).
A decreasing trend of mortality was observed as base-
line TC increased (Figure S2). Mortality was 87.7 per
1,000 person-years in participants with the reference TC
category (4.5–4.9 mmol/L). Mortality of participants with
the lowest TC category (<3.0 mmol/L) was highest (138.7
per 1,000 person-years, aHR=1.42, 95% CI = 1.24–1.64,
P < .001). Missing TC was also associated with higher
mortality (aHR = 1.40, 95% CI = 1.22–1.60, P < .001).
Sensitivity Analyses
There was evidence that the association between TC and
mortality varied according to sex (P for interaction = .006)
and prescription of lipid-lowering drugs (P for interac-
tion = .001) (Table S2). Higher risk of mortality for low
TC was more evident in women (e.g., for TC <3.0 mmol/
L, aHR = 1.21, 95% CI = 1.01–1.46, P = .04 in men;
aHR = 1.80, 95% CI = 1.46–2.22, P < .001 in women).
TC level associated with higher mortality was <4.5 mmol/
L in participants who were not prescribed lipid-lowering
drugs (e.g., for TC 4.0–4.4 mmol/L, aHR = 1.38, 95%
CI = 1.12–1.69, P = .003) but <3.0 mmol/L in participants
prescribed lipid-lowering drugs (aHR = 1.33, 95%
CI = 1.14–1.56, P < .001). The relationships between
HbA1c, BP, and TC and mortality in the main analysis
were retained after excluding participants who died in the
first 6 months of follow-up (Table S3).
Combined Effects of High-Risk Categories
Based on the analysis with the lowest risk categories as
reference, HbA1c less than 6.0% (<42 mmol/mol) or
≥8.0% (≥64 mmol/mol), BP less than 135/75 mmHg, and
TC <3.0 mmol/L for men and <4.5 mmol/L for women
were identified as the high-risk categories for mortality.
Table 3. Associations Between Glycosylated Hemoglobin (HbA1c), Blood Pressure, and Total Cholesterol and All-
Cause Mortality (N = 25,966)
Factor Deaths, n/N %
Mortality (1,000
Person-Years)
Unadjusted Adjusted
Hazard Ratio (95% Confidence Interval) P-Value
HbA1c, % (mmol/mol)
<6.0 (<42) 301/1,387 21.7 134.9 1.21 (1.03–1.42) .02 1.04 (0.88–1.23) .67
6.0–6.4 (42–47) 506/2,976 17.0 102.1 0.92 (0.80–1.05) .21 0.91 (0.79–1.05) .19
6.5–6.9 (48–52) 1,081/7,463 14.5 85.6 0.77 (0.68–0.87) <.001 0.84 (0.74–0.96) .009
7.0–7.4 (53–57) 648/4,700 13.8 80.9 0.72 (0.63–0.83) <.001 0.80 (0.70–0.91) .001
7.5–7.9 (58–63) 453/2,777 16.3 98.6 0.88 (0.77–1.02) .09 0.90 (0.79–1.04) .15
8.0–8.4 (64–68) 324/1,780 18.2 111.5 Reference Reference
≥8.5 (≥69) 641/3,006 21.3 133.1 1.20 (1.05–1.37) .009 1.04 (0.91–1.19) .55
Missing 536/1,877 28.6 195.9 1.76 (1.53–2.02) <.001 1.01 (0.86–1.19) .88
Blood pressure, mmHg
<130/70 982/4,116 23.9 151.7 1.89 (1.67–2.13) <.001 1.52 (1.34–1.72) <.001
≥130/70 & <135/75 815/4,416 18.5 112.3 1.40 (1.23–1.58) <.001 1.30 (1.14–1.48) <.001
≥135/75 & <140/80 719/4,749 15.1 90.3 1.12 (0.99–1.27) .08 1.11 (0.97–1.27) .13
≥140/80 & <145/85 685/4,746 14.4 85.6 1.06 (0.93–1.21) .35 1.09 (0.95–1.24) .23
≥145/85 & <150/90 349/2,534 13.8 80.5 Reference Reference
≥150/90 & <155/95 231/1,717 13.5 80.3 1.00 (0.85–1.18) .98 0.97 (0.82–1.14) .70
≥155/95 419/2,663 15.7 94.0 1.17 (1.01–1.35) .03 1.05 (0.91–1.22) .49
Missing 290/1,025 28.3 191.2 2.38 (2.04–2.78) <.001 1.38 (1.18–1.61) <.001
Total cholesterol, mmol/L
<3.0 455/2,033 22.4 138.7 1.58 (1.39–1.80) <.001 1.42 (1.24–1.64) <.001
3.0–3.4 630/3,857 16.3 97.6 1.11 (0.99–1.25) .08 1.15 (1.02–1.29) .02
3.5–3.9 787/5,247 15.0 89.2 1.02 (0.91–1.14) .78 1.08 (0.96–1.21) .20
4.0–4.4 728/4,666 15.6 92.9 1.06 (0.94–1.19) .33 1.16 (1.03–1.30) .01
4.5–4.9 468/3,158 14.8 87.7 Reference Reference
5.0–5.4 276/1,822 15.1 90.6 1.03 (0.89–1.20) .67 1.00 (0.85–1.16) .96
≥5.5 347/2,288 15.2 91.4 1.04 (0.91–1.20) .56 0.99 (0.86–1.13) .85
Missing 799/2,895 27.6 185.9 2.12 (1.89–2.38) <.001 1.40 (1.22–1.60) <.001
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Mortality risk according to combinations of HbA1c, BP,
and TC risk categories is shown in Table 4. Of partici-
pants included in this analysis (N = 22,248), 6,940 (31%)
had lower risk categories for all three factors (mortality
69.3 per 1,000 person-years). Mortality was 93.9 per
1,000 person-years (aHR = 1.34, 95% CI = 1.23 to 1.47,
P < .001) in participants with one high-risk category
(n = 9,862, 44%); 120.4 per 1,000 person-years
(aHR = 1.71, 95% CI = 1.55–1.90, P < .001) in partici-
pants with two high-risk categories (n = 4,686, 21%); and
156.9 per 1,000 person-years (aHR = 2.08, 95%
CI = 1.76–2.44, P < .001) in participants with three high-
risk categories (n = 760, 3%).
DISCUSSION
Main Findings
Relationships between HbA1c, BP, and TC and all-cause
mortality were investigated in a large population-based
sample of very old adults with type 2 diabetes mellitus.
Low (<6.0%, <42 mmol/mol) or high (≥8.0%, ≥64 mmol/
mol) HbA1c and low BP (<135/75 mmHg) and TC
(<3.0 mmol/L) were associated with greater mortality,
but causal relationships were not established between the
high-risk ranges of these cardiovascular risk factors and
mortality because of the observational nature of this
study.
Greater risk of microvascular and cardiovascular com-
plications could explain the association between high
HbA1c and mortality.13,21 Hypoglycemia might partly
explain the association between low HbA1c and greater
mortality, but the retrospective analysis of the ACCORD
study suggested that severe hypoglycemia could not
explain the greater risk of mortality in the intensive treat-
ment group.22 The current study adjusted for several
covariates in the analyses, but the possibility of confound-
ing cannot be completely excluded. Unmeasured confound-
ing factors such as frailty, physical activity, and
proteinuria might modify the associations between HbA1c,
BP, and TC and mortality.23–25 Confounding by indication
might also arise if therapeutic interventions are reduced or
increased in individuals approaching the end of life. Partic-
ipants with missing values for BP and TC had greater risk
of mortality, which indicates that physicians may be less
likely to test individuals who are reaching the end of their
lives. If individuals with worse conditions have low
HbA1c, BP, and TC, reverse causality may explain the
associations between the risk factors and mortality, which
is potentially problematic in studies on mortality in older
people with short follow-up. In the current study cohort,
because the associations between low HbA1c, BP, and TC
and greater mortality were retained in the analysis of par-
ticipants after excluding those who died in the first
6 months of follow-up, reverse causation might not
completely explain the associations. Further research on
underlying mechanisms of the association between HbA1c,
BP, and TC and mortality is needed, which could also
inform individualized management of this heterogeneous
population.
The associations between low HbA1c, BP, and TC
and higher mortality have been reported in previous
observational studies. A recent study with the CPRD
demonstrated that HbA1c of 7.25% to 7.75% (56–
61 mmol/mol), systolic BP of 135 to 145 mmHg, diastolic
BP of 82.5 to 87.5 mmHg, and TC of 3.5 to 4.5 mmol/L
were associated with the lowest risk of mortality in indi-
viduals with type 2 diabetes mellitus with a mean age of
Table 4. Mortality Risk According to Combinations of Glycosylated Hemoglobin (HbA1c), Blood Pressure, and
Total Cholesterol Risk Categories (N = 22,248)
Number of High
Risk Categories
HbA1c,
%
Blood
Pressure,
mmHg
Total
Cholesterol,
mmol/L
Deaths,
n/N %
Mortality (1,000
Person-Years)
Adjusted Hazard Ratio
(95% Confidence Interval)
P-
Value
0 – – – 830/6,940 12.0 69.3 Reference
1 <6.0 – – 59/429 13.8 82.1 0.98 (0.75–1.28) .89
≥8.0 – – 302/1,884 16.0 96.6 1.28 (1.12–1.46) <.001
– <135/75 – 631/3,478 18.1 109.5 1.37 (1.23–1.52) <.001
– – Men <3.0,
Women <4.5
556/4,071 13.7 80.8 1.41 (1.25–1.58) <.001
2 <6.0 <135/75 – 79/263 30.0 199.3 2.29 (1.79–2.92) <.001
<6.0 – Men <3.0,
Women <4.5
58/318 18.2 109.9 1.62 (1.23–2.13) .001
≥8.0 <135/75 – 212/856 24.8 159.6 1.77 (1.51–2.08) <.001
≥8.0 – Men <3.0,
Women <4.5
188/1,021 18.4 111.5 1.60 (1.35–1.89) <.001
– <135/75 Men <3.0,
Women <4.5
382/2,228 17.1 103.4 1.66 (1.45–1.90) <.001
3 <6.0 <135/75 Men <3.0,
Women <4.5
59/229 25.8 160.7 2.09 (1.59–2.75) <.001
≥8.0 <135/75 Men <3.0,
Women <4.5
130/531 24.5 155.2 2.06 (1.68–2.53) <.001
Participants with missing values for HbA1c, blood pressure, or total cholesterol were excluded from the analysis (n = 3,718).
Low risk for mortality: HbA1c 6.0–7.9% (42–63 mmol/mol); blood pressure ≥135/75 mmHg; total cholesterol ≥3.0 mmol/L for men and ≥4.5 mmol/L for
women.
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66.13 The relationship between HbA1c and mortality
observed in that study was similar to that found in the
current study, but this study suggests a higher optimal
range for BP and TC. Higher percentages of women in the
study cohort might have partly caused the difference in the
relationship between TC and mortality. The current results
were generally in line with findings from previous studies
in older adults. HbA1c of 6.0% to 7.9% (42–63 mmol/
mol) were associated with lower risk of mortality in indi-
viduals aged 80 and older with diabetes mellitus,16 which
was consist with the lower risk range based on the present
study. The association between low BP and higher mortal-
ity was observed in individuals with type 2 diabetes melli-
tus and renal impairment (mean age 75)18 and in
individuals aged 80 and older, including 25% of partici-
pants with diabetes mellitus.26 It was shown that TC of
<5.5 mmol/L tended to be associated with higher mortal-
ity, with the lowest at approximately 6 mmol/L in partici-
pants aged 80 and older.27
Evaluation of appropriateness of drug use would be
the next step for better management. Frequent prescribing
of antidiabetic and cardiovascular drugs has been found
in very old adults who were newly diagnosed with type 2
diabetes mellitus.28 A recent study in the United States
suggested possible overtreatment with antidiabetic drugs
in older adults with diabetes mellitus, especially those
treated with insulin or sulphonylureas, which may cause
severe hypoglycemia.29 A meta-analysis of randomized
controlled trials indicated that antihypertensive medica-
tions reduced the risk of CVD but did not reduce mortal-
ity in participants aged 80 and older.30 Use of lipid-
lowering drugs should be individualized because of the
biological heterogeneity of people aged 80 and older.31
The majority of participants with low HbA1c, BP, and
TC in the current study cohort were under treatment
with antidiabetic, antihypertensive, and lipid-lowering
drugs, respectively, which may suggest possible overtreat-
ment in primary care in the United Kingdom. More evi-
dence is needed for informed decision-making to initiate
or discontinue these medications for very old adults with
diabetes mellitus.
Strengths and Limitations
A strength of the present study was the inclusion of a
large, representative sample of general population in pri-
mary care across the United Kingdom. Given that it has
been difficult to include very old people in clinical trials
because of safety reasons, the findings are considered com-
plementary and of importance in drawing attention to the
possible negative associations between low HbA1c, BP,
and TC and survival in very old people with diabetes mel-
litus.
There are also some limitations of the study. First,
longer follow-up could reach other conclusions because
individuals with a longer life expectancy may be expected
to obtain health benefits from tight control of cardiovas-
cular risk factors.6 Second, HbA1c, BP, and TC values
from the 12-month baseline period were included in the
analyses, but these variables might fluctuate over time,
and long-term management might affect clinical out-
comes. Third, cause of death, which is not immediately
available in the CPRD, was not analyzed. Additional
information on cause of death would aid interpretation
of the present study results. Fourth, an individual’s age
may directly inform treatment recommendations, but
stratified evaluation of individuals according to frailty
and other characteristics might be more important
because of the heterogeneity of older adults.6 Finally,
there were some limitations commonly intrinsic to retro-
spective studies with electronic health records. The analy-
ses depended on completeness and accuracy of CPRD
records. Information was not available on whether partic-
ipants actually took medications prescribed. Many of
these limitations could be overcome through the conduct
of randomized controlled trials, but these have yet to be
reported for very old people with type 2 diabetes melli-
tus.
CONCLUSION
The present study demonstrated that low HbA1c, BP, and
TC might be associated with higher mortality in very old
adults with type 2 diabetes mellitus. These observational
data may suggest that stringent targets for the cardiovascu-
lar risk factor reduction are not always optimal in this
population. Additional research is required to understand
these associations observed in this study and to identify
optimal HbA1c, BP, and TC during therapeutic interven-
tion for vulnerable old people at possible high risk of
CVD.
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and Mortality.
Table S1. Cox Models.
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